Acutaas Chemicals Ltd Q3 FY2025 Concall Summary

Key Takeaways

• Guidance raised, CDMO-led beat: Revenue grew 65.2% YoY and the company revised its FY25 growth target upward from 30% to 35%, driven by a CDMO ramp-up that is still in early innings.
• Margins hit multi-year highs: EBITDA margin reached 25%, up 904 bps YoY, as the richer CDMO mix lifted gross margins 333 bps; management expects this trajectory to continue into FY26.
• The CDMO pipeline is the story, but details are now opaque: A second contract begins commercial supply in FY26, and the company targets ₹1,000 crores in CDMO revenue by FY28, yet management has stopped disclosing the segment split, citing partner confidentiality.
• Specialty chemicals dragged, recovery promised: The segment declined ~11% sequentially on commodity price pressure and deferred orders; management calls the dip temporary and expects Q4 normalization.
• What to watch next quarter: Whether the Q4 normalization in Specialty Chemicals materializes, the pace of CDMO ramp-up as Block 1 commercializes, and any further reduction in financial disclosure granularity.

CDMO Ramp-Up & Pipeline

• Second contract underway: Commercial supply from the second CDMO contract, housed in Block 2 of Unit-2, will definitely start from FY26; validation is currently under review.
• Block 1 imminent: Block 1 at the Ankleshwar site is expected to be commercialized by the end of the March quarter, adding near-term capacity for the Pharma Intermediates business.
• FY28 ambition: Overall CDMO business is expected to reach approximately ₹1,000 crores by FY28, up from just ₹80-90 crores in the last financial year; the current year has already more than doubled that base.
• Pipeline beyond the flagship: Several additional CDMO projects have progressed to final stages, with most expected to begin commercialization by FY26; a robust pipeline of molecules in Phase-III and later clinical stages is set to mature in FY27, FY28, and FY29.
• Capacity in place: Unit-2 capacity will cater largely for the next 2 to 3 years' requirement, with Block 2 already inaugurated and Block 1 coming online; management states demand is not an issue, with timing dependent on when innovators are ready to transfer.
• Disclosure blackout: Management has stopped providing segment-wise revenue splits and the Pharma Intermediates business mix breakup (generic API, innovator pharma, CDMO, import substitutes) from this year onwards, citing lessons learned about partner confidentiality and generating their own competition.

Nareshkumar Patel: "We learned this mistake. And now that's why we are saying we are not breaking it up. We are also learning this how to handle disclosures, because disclosure is only not for the investors, but also for our partners who are buying from us."

Margin Trajectory & Drivers

• Gross margin expansion: Gross margin expanded 333 bps YoY and 281 bps QoQ to 46.2%, driven by a better product mix as higher-margin CDMO revenue scaled up.
• EBITDA leap: EBITDA margin at 25% was up 904 bps YoY and 198 bps QoQ, benefiting from both the gross margin lift and operating leverage.
• FY26 peak promised: For FY26 full year, management expects blended margin to reach the peak or highest margin ever reported by Ami Organics, with sequential improvement from Q1 to Q4.
• CDMO margin ceiling: With commercialization of the other two blocks, operational efficiency will push EBITDA margins beyond 25%, potentially reaching 27% to 30%, though management maintains conservative guidance relative to pure-play CDMO peers since this is an intermediate business, not API.
• Semicon margin upside: The semiconductor chemicals business (via Baba Fine Chem) carries margins much higher than Pharma and CDMO, varying from 40% to 65% depending on product and scale.

Abhishek Patel: "And for FY '26 for full year, we are expecting this margin on a blended basis to reach at a peak or highest margin ever reported by Ami Organics."

Specialty Chemicals: The Drag

• Sequential decline: Specialty Chemicals revenue dropped ~11% QoQ, primarily due to lower volume in the commodity chemical business; the BFC (Baba Fine Chem) business was flat YoY but showed steady sequential growth.
• Commodity pressure: The acquired Gujarat Organics portfolio saw topline erode by 30% due to price pressure and raw material pass-through, though market share was sustained and EBITDA was maintained at double-digit margins.
• Deferred orders in cosmetics: Spec-Chem saw small degrowth from deferred supply orders in the commodity spectrum of cosmetics and parabens, plus some orders deliberately left on pricing grounds.
• Recovery thesis: Management characterizes the Q3 degrowth as cyclical and temporary; Q1 and Q2 ex-BFC Spec-Chem performed very well, and Q4 is expected to normalize, with full-year growth still expected above 15%.
• BFC ramp deferred: BFC will not ramp up significantly in FY26; meaningful uptake is expected from FY27 onwards, with seeding done in Korea and Japan and validation batches already shipping.

Abhishek Patel: "No, not in FY '26, but it can go on from FY '27. It has already started. As we mentioned, we see Q2 as a bottom out quarter for BFC. It has already started moving up. But slowly, slowly, it will ramp up, not in very big way in FY '26, but '27 onwards."

New Growth Engines: Electrolytes & Semicon

• Electrolyte additive expansion: The portfolio has grown from 2 to more than 12 electrolyte additives; qualification staging has started with both existing and new customers, and a 4,000-metric-ton plant is being built with CAPEX of ₹170 crores, backed by signed long-term supply contracts.
• Electrolyte margin profile: Margins will be better than Specialty but lower than Pharma; the CAPEX is on track for completion by H1 FY26.
• Semiconductor chemicals: Baba Fine Chem is producing photoresist chemicals, with monomers and chemicals being sent to Japan and Korea for semiconductor backend packaging; this is expected to mature in the next couple of years.
• Semicon margin outlier: Margins in this segment may vary from 40% to 65%, depending on product and scale, making it the highest-margin opportunity in the portfolio.
• Cautious on battery: The company is adopting a cautious approach to the broader battery chemical segment, focusing CAPEX only on additives where long-term contracts are in place.

Nareshkumar Patel: "Semicon is a very different ball of game, where we are the only company in India, who are right now have a good situation and position ourselves in this basic chemical supply, where the margins are much higher than the Pharma as well as CDMO, which it may vary from 40% to 65%."

Generic Base & Legacy Visibility

• 2040 visibility: The company has developed molecules for generic application up to 2040, providing a long-dated steady growth floor secured by customer commitments.
• Apixaban ramp: Apixaban patent expires in 2026, and demand has already started for API manufacturing; the Q3 ramp was small, Q4 will be slightly higher, and by FY26 volumes are expected to reach a very moderate level after being minimized for the last couple of financial years.
• Rivaroxaban ramp: Rivaroxaban expiry is in FY26-27, with ramp-up expected by the end of this year; the company is still selling some quantities to partners in Europe and India.
• Raw material stabilization: Apart from CDMO patented-product agreements, raw material prices have stabilized; contracts that shifted to spot basis during the disruption have now returned to contract basis, and rolling forecasts are giving good visibility for the next 1 to 1.5 years.

Nareshkumar Patel: "we have business security till 2040. We had already done developing molecules for generic application up to 2040, which will cater our steady growth up to 2040 with the customer also secure."

Financial Position & Capacity

• Working capital turnaround: Working capital days reduced to 95 from 108 in H1 FY25, driven by improved debtor days and stable inventory.
• Cash conversion: Strong cash flow from operations of ₹119 crores represented 81% of EBITDA, reflecting the working capital improvement.
• Capacity headroom: Unit-1 Sachin is over 70% utilized; Unit-2 Block 3 is at 50%; Unit-3 is at 50%; Spec-Chem capacity at 50% utilization will cater for the next 3 years.
• Asset turns target: Management targets 3x asset turns on any CAPEX deployed.
• Korean JV on hold: The Korean JV (solution business) remains status quo; the company does not want to rush into a market yet to fully develop and will not allocate capital until a relevant trigger appears.

Guidance & Commitments

Key Metrics